CD4++ T-cell counts and plasma HIV-1 RNA levels beyond 5 years of highly active antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 57, Issue 5, 2011, Pages 421-428

  Li, Xiuhong ^a   Margolick, Joseph B ^a   Jamieson, Beth D ^b   Rinaldo, Charles R ^c   Phair, John P ^d   Jacobson, Lisa P ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

age effects; CD4+ T cells; HAART; HIV 1 RNA; response

Indexed keywords

ABACAVIR; ATAZANAVIR; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; SAQUINAVIR; TENOFOVIR DISOPROXIL; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; TIME FACTORS;

EID: 80051547981     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31821e9f21     Document Type: Article

References (50)

1. Detels R, Muñoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA. 1998;280:1497-1503. (Pubitemid 28507402)
2. Jacobson LP, Li R, Phair J, et al. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression. Am J Epidemiol. 2002;155:760-770. (Pubitemid 34297657)
3. Tarwater PM, Margolick JB, Jin J, et al. Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27:168-175. (Pubitemid 32595168)
4. Schneider MF, Gange SJ, Williams CM, et al. Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS. 2005;19:2009-2018. (Pubitemid 41669026)
5. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med. 2007; 146:87-95. (Pubitemid 351640011)
6. Valcour VG, Sacktor NC, Paul RH, et al. Insulin resistance is associated with cognition among HIV-1-infected patients: the Hawaii Aging With HIV Cohort. J Acquir Immune Defic Syndr. 2006;43:405-410. (Pubitemid 44737096)
7. Anastos K, Barron Y, Cohen MH, et al. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med. 2004;140:256-264.
8. Chene G, Sterne JA, May M, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet. 2003;362:679-686.
9. MacArthur RD, Perez G, Walmsley S, et al. Comparison of prognostic importance of latest CD4+ cell count and HIV RNA levels in patients with advanced HIV infection on highly active antiretroviral therapy. HIV Clin Trials. 2005;6:127-135. (Pubitemid 41341727)
10. Tarwater PM, Gallant JE, Mellors JW, et al. Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users. AIDS. 2004; 18:2419-2423. (Pubitemid 40065909)
11. Lanoy E, May M, Mocroft A, et al. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. AIDS. 2009;23: 2199-2208.
12. Kaufmann GR, Furrer H, Ledergerber B, et al. Characteristics, determinants, and clinical relevance of CD4 T-cell recovery to ,500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis. 2005;41:361-372. (Pubitemid 41022115)
13. Kaufmann GR, Perrin L, Pantaleo G, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med. 2003; 163:2187-2195. (Pubitemid 37248783)
14. Li X, Chu H, Gallant JE, et al. Bimodal virological response to antiretroviral therapy for HIV infection: an application using a mixture model with left censoring. J Epidemiol Community Health. 2006;60:811-818. (Pubitemid 44298835)
15. Chu H, Gange SJ, Yamashita TE, et al. Individual variation in CD4 cell count trajectory among human immunodeficiency virus-infected men and women on long-term highly active antiretroviral therapy: an application using a Bayesian random change-point model. Am J Epidemiol. 2005;162: 787-797. (Pubitemid 41437766)
16. Kelley CF, Kitchen CM, Hunt PW, et al. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis. 2009;48:787-794.
17. Mocroft A, Phillips AN, Gatell J, et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet. 2007;370:407-413. (Pubitemid 47176633)
18. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007;44:441-446. (Pubitemid 46147630)
19. Detels R, Phair JP, Saah AJ, et al. Recent scientific contributions to understanding HIV/AIDS from the Multicenter AIDS Cohort Study. J Epidemiol (Japan). 1992;2:S11-S19.
20. Dudley J, Jin S, Hoover D, et al. The Multicenter AIDS Cohort Study: retention after 9 1/2 years. Am J Epidemiol. 1995;142:323-330.
21. Kaslow RA, Ostrow DG, Detels R, et al. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol. 1987;126:310-318. (Pubitemid 17102758)
22. Giorgi JV, Cheng HL, Margolick JB, et al. Quality control in the flow cytometric measurement of T-lymphocyte subsets: the multicenter AIDS cohort study experience. The Multicenter AIDS Cohort Study Experience. Clin Immunol Immunopathol. 1990;55:173-186. (Pubitemid 20137384)
23. Schenker EL, Hultin LE, Bauer KD, et al. Evaluation of a dual-color flow cytometry immunophenotyping panel in a multicenter quality assurance program. Cytometry. 1993;14:307-317. (Pubitemid 23089082)
24. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41(RR-17):1-19.
25. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services; December 1, 2009:1-161. Available at: http://aidsinfo.nih.gov/contentfiles/Adultand AdolescentGL.pdf. Accessed July 21, 2010.
26. Kleeberger CA, Phair JP, Strathdee SA, et al. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2001;26:82-92. (Pubitemid 32115053)
27. Daka D, Loha E. Relationship between total lymphocyte count (TLC) and CD4 count among peoples living with HIV, Southern Ethiopia: a retrospective evaluation. AIDS Res Ther. 2008;5:26.
28. Teixeira L, Valdez H, McCune JM, et al. Poor CD4 T-cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS. 2001;15:1749-1756. (Pubitemid 32939234)
29. Darby SC, Ewart DW, Giangrande PL, et al. Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. UK Haemophilia Centre Directors' Organisation. Lancet. 1996;347:1573-1579. (Pubitemid 26170873)
30. Butt AA, Dascomb KK, DeSalvo KB, et al. Human immunodeficiency virus infection in elderly patients. South Med J. 2001;94:397-400. (Pubitemid 33643428)
31. Woldemichael G, Christiansen D, Thomas S, et al. Demographic characteristics and survival with AIDS: health disparities in Chicago, 1993-2001. Am J Public Health. 2009;99(suppl 1):S118-S123.
32. Sabin CA, Smith CJ, d'Arminio Monforte A, et al. Response to combination antiretroviral therapy: variation by age. AIDS. 2008;22: 1463-1473.
33. Grabar S, Kousignian I, Sobel A, et al. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS. 2004;18:2029-2038. (Pubitemid 39463356)
34. Grabar S, Weiss L, Costagliola D. HIV infection in older patients in the HAART era. J Antimicrob Chemother. 2006;57:4-7. (Pubitemid 43057052)
35. Clinical Management and Treatment of HIV Infected Adults in Europe (Version 5). Available at: http://www.europeanaidsclinicalsociety.org/guide linespdf/1-Treatment-of-HIV-Infected-Adults.pdf. Accessed July 21, 2010.
36. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300:555-570.
37. Lukito W, Wattanapenpaiboon N, Savige GS, et al. Nutritional indicators, peripheral blood lymphocyte subsets and survival in an institutionalised elderly population. Asia Pac J Clin Nutr. 2004;13:107-112. (Pubitemid 38885709)
38. Patrick L. Nutrients and HIV: part two-vitamins A and E, zinc, Bvitamins, and magnesium. Altern Med Rev. 2000;5:39-51. (Pubitemid 30132071)
39. Anastos K, Schneider MF, Gange SJ, et al. The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr. 2005;39:537-544. (Pubitemid 41098467)
40. Heckman BD, Catz SL, Heckman TG, et al. Adherence to antiretroviral therapy in rural persons living with HIV disease in the United States. AIDS Care. 2004;16:219-230. (Pubitemid 38183585)
41. Parienti JJ, Massari V, Descamps D, et al. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine-or efavirenzbased antiretroviral therapy. Clin Infect Dis. 2004;38:1311-1316. (Pubitemid 38608576)
42. Roge BT, Barfod TS, Kirk O, et al. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study. HIV Med. 2004;5:344-351. (Pubitemid 39276332)
43. Tuboi SH, Harrison LH, Sprinz E, et al. Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil. J Acquir Immune Defic Syndr. 2005;40:324-328. (Pubitemid 41533073)
44. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350:1850-1861. (Pubitemid 38917251)
45. van Leeuwen R, Katlama C, Murphy RL, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS. 2003;17:987-999. (Pubitemid 36549710)
46. Cozzi-Lepri A, Phillips AN, d'Arminio Monforte A, et al. Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study. J Infect Dis. 2002;185:1062-1069. (Pubitemid 34297764)
47. Keiser P, Nassar N, White C, et al. Comparison of nevirapine-and efavirenzcontaining antiretroviral regimens in antiretroviral-naive patients: a cohort study. HIV Clin Trials. 2002;3:296-303. (Pubitemid 34830680)
48. Matthews GV, Sabin CA, Mandalia S, et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS. 2002;16:53-61. (Pubitemid 34062182)
49. Lau B, Gange SJ, Moore RD. Interval and clinical cohort studies: epidemiological issues. AIDS Res Hum Retroviruses. 2007;23:769-776. (Pubitemid 47047915)
50. Lau B, Gange SJ, Kirk GD, et al. Evaluation of human immunodeficiency virus biomarkers: inferences from interval and clinical cohort studies. Epidemiology. 2009;20:664-672.